Tweet
Novel Plant-Derived Compound May Be Game-Changer for Drug-Resistant Tuberculosis
A plant-derived compound was shown in a recent study to kill strains of tuberculosis that were resistant to existing therapies.
The compound was found in a plant native to North America, and was not only able to suppress dormant TB bacteria from resurfacing but also didn’t damage the gut microbiome.
Tuberculosis is the second-leading killer of humans from an infectious disease worldwide, and has been developing resistance to many of the antibiotics previously used to treat it.
Caused by a species of bacteria that invades the respiratory system called Mycobacterium tuberculosis, it can also affect the heart, brain, and spinal column.
A new study published in the journal Anti-inflammatory Nutraceuticals and Chronic Diseases, found that sanguinarine, a derivative of bloodroot, a wildflower found in North America, could combat multidrug-resistant tuberculosis (MRTB) after being genetically modified to reduce its natural toxicity.
TB is treated with multiple medications over a 6-month period, exposing the human organism to substantial weakening. By contrast, the sanguinarine selectively targeted the bacteria responsible for MRTB, leaving harmless and beneficial bacteria intact.
However, in its natural form, sanguinarine is toxic to human cells, so Dr. Jim Sun, senior author and assistant professor at the University of British Columbia’s Department of Microbiology and Immunology, led a team to genetically reduce the toxicity of the phytochemical while increasing its potency as a tuberculosis killer.
The compound was found in a plant native to North America, and was not only able to suppress dormant TB bacteria from resurfacing but also didn’t damage the gut microbiome.
Tuberculosis is the second-leading killer of humans from an infectious disease worldwide, and has been developing resistance to many of the antibiotics previously used to treat it.
Caused by a species of bacteria that invades the respiratory system called Mycobacterium tuberculosis, it can also affect the heart, brain, and spinal column.
A new study published in the journal Anti-inflammatory Nutraceuticals and Chronic Diseases, found that sanguinarine, a derivative of bloodroot, a wildflower found in North America, could combat multidrug-resistant tuberculosis (MRTB) after being genetically modified to reduce its natural toxicity.
TB is treated with multiple medications over a 6-month period, exposing the human organism to substantial weakening. By contrast, the sanguinarine selectively targeted the bacteria responsible for MRTB, leaving harmless and beneficial bacteria intact.
However, in its natural form, sanguinarine is toxic to human cells, so Dr. Jim Sun, senior author and assistant professor at the University of British Columbia’s Department of Microbiology and Immunology, led a team to genetically reduce the toxicity of the phytochemical while increasing its potency as a tuberculosis killer.
Comment